AQP4x Antibody #60789
- WB
Supporting Data
| REACTIVITY | M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 32 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
AQP4x Antibody recognizes endogenous levels of total mouse AQP4x protein with an extended C-terminal tract.
Species Reactivity:
Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of mouse AQP4x protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Aquaporins (AQP) are integral membrane proteins that serve as channels in the transfer of water and small solutes across the membrane. There are 13 isoforms of AQP that express in different types of cells and tissues (1,2). AQP1 is found in blood vessels, kidney, eye, and ear. AQP2 is found in the kidney, and it has been shown that the lack of AQP2 results in diabetes (1,3). AQP4 is present in the brain, where it is enriched in astrocytes (1,2,4). AQP5 is found in the salivary and lacrimal gland, AQP6 in intracellular vesicles in the kidney, AQP7 in adipocytes, AQP8 in kidney, testis, and liver, AQP9 is present in liver and leukocytes, and AQP10-11 in the intestine (1,3,4). AQPs are essential for the function of cells and organs. It has been shown that AQP1 and AQP4 regulate the water homeostasis in astrocytes, preventing cerebral edema caused by solute imbalance (5). Several studies have shown the involvement of AQPs in the development of inflammatory processes, including cells of innate and adaptive immunity (6,7).
The mouse AQP4x has an extended sequence at the C-terminal (ex) as a result of a codon readthrough during alternative splicing (8). The C-terminal extension in the mouse AQP4x changes the localization to a more perivascular polarization (8). Programmed translational readthrough could occur also in human AQP4x (9).
- Takata, K. et al. (2004) Prog Histochem Cytochem 39, 1-83.
- Echevarría, M. and Ilundáin, A.A. (1998) J Physiol Biochem 54, 107-18.
- Gomes, A. et al. (2018) Front Chem 6, 238.
- Xu, M. et al. (2017) Adv Exp Med Biol 969, 81-103.
- Kobayashi, H. et al. (2004) J Pharmacol Sci 96, 264-70.
- Meli, R. et al. (2018) Front Physiol 9, 101.
- Ishibashi, K. et al. (1998) Biochem Biophys Res Commun 244, 268-74.
- Sapkota, D. et al. (2019) Cell Rep 26, 594-607.e7.
- De Bellis, M. et al. (2017) Glia 65, 790-803.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.